ÅëÇÕ°Ë»ö
Diamond
ÇູÀÌ °¡µæÇÑ¢½
(¾ÆÀ̵ð ekfrhdhssk)
¸ðµÎµé ÇູÇϼ¼¿ä~¢½

ÀÀ±Þ¾à¹° Á¤¸®

ÇູÀÌ °¡µæÇÑ¢½ > ¹®¼­¹Ú½º > ±âŸ·¹Æ÷Æ® | 2008/08/04 ±¸¸Å(1) ¤Ó Á¶È¸(95)
¹®¼­ ¿ä¾àÁ¤º¸
±¸¸ÅÀÚ Æò°¡
  • ÆÇ¸Å°¡°Ý : 1,500¿ø (5Pages)
  • ÀúÀ۽ñâ : 2008/05
  • Ãßõµ¶ÀÚ : ´ëÇлý,.
¹®¼­ »ó¼¼Á¤º¸
¸®Æ÷Æ® ½ºÅ©¸°  (1/1 screen)
¡Ø ÃÖ´ë 10ÆäÀÌÁö±îÁö ¸®Æ÷Æ® ½ºÅ©¸° À̹ÌÁö¸¦ »ý¼ºÇÕ´Ï´Ù.
¡Ø 5ÆäÀÌÁö ÀÌ»óÀÇ ÀÚ·áÀÎ °æ¿ì À̹ÌÁö¸¦ Ŭ¸¯ÇϽøé 2,4 ÆäÀÌÁö¿¡ ÇØ´çÇÏ´Â Å« À̹ÌÁö¸¦ È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù
¼Ò°³±Û ÀÀ±Þ¾ç¹°¿¡°üÇÏ¿¡ Á¤¸®ÇسõÀº·¹Æ÷Æ®ÀÔ´Ï´Ù.
¸ñÂ÷ @3 classes of adrenergic receptor
@ ÀÀ±Þ½Ç ÀÀ±Þ ¾à¹°
1) nitroglycerin(10mg/10ml)
2) Sodium Nitroprusside(Nipride)
3) Dobutamine(Dobutrex) 250mg/5ml
4) Dopamin (200mg/5ml)
º»¹®³»¿ë @3 classes of adrenergic receptor
1) alpha stimulation
¨ç alpha 1 : vasoconstriction
¨è alpha 2 : decrease norepinephrine release
2) beta 1 : cardiac
¨ç positive : ½É¹Úµ¿ º¯µ¿, ±Ù¼öÃà, Àüµµ º¯È­
¨è increase HR, Contractility, Speed of conduction(Àüµµ)
3) Beta 2 : Lungs
¨ç vasodilation(È®Àå)
¨è Bronchodilation
4) Dopaminergic stimulation
¨ç Dopaminergic 1-smooth muscle
: Renal, ³»Àå, °ü»óµ¿¸Æ, ´ë³ú µ¿¸Æ È®Àå
¨è Dopaminergic 2-autonomic ganglia / symp nerve endings
: inhibits aldosterone synthesis / release
@ General consideration
1) infusion pump
2) monitoring : V/S, Ç÷¿ªµ¿ÇÐ, tissue perfusion
3) central line
4) titrate(ÀûÁ¤ÇÏ´Ù) slowly
5) Assume incompatibility(ºÒÈ­ÇÕ)
@ ÀÀ±Þ½Ç ÀÀ±Þ ¾à¹°
1) nitroglycerin(10mg/10ml)
¨ç mechanism of action
-venodilation : ¡éMVO2, ¡épreload
-dilates coronary arteries
-arteriolar dilaton(>1~2mcg/kg/min)
¨è Dosage
-mcg/min
-mix in glass bottle D5W or NS : 50mg/250cc, 100mg/250cc
-onset : 1~2min
-duration : 4~5min
-titrate : 50~200 mcg/min
-indication : CHF(congestive heart failure, ¿ïÇ÷¼º ½ÉºÎÀü), Pulmonary edema(ÆóºÎÁ¾), Hypertension, Angina(Çù½ÉÁõ), Acute MI
¨é Adverse reactions
: Hypotension, Tachycardia, Headache, Coronary steal
¨ê Nursing concerns
: Maintain BP, NTG binds to PVC(use non-pvc tubing, glass bottle system)
2) Sodium Nitroprusside(Nipride)
¨ç mechanism of action
-potent(Áß¿ä) peripheral(¸»ÃÊ) vasodilator
-acts on both arterial and venous smooth muscle
-direct action on systemic, coronary, pulmonary and renal circulation
-preload and afterload reduction
-decrease MVO2
¨è Dosage
-mcg/kg/min
-mix in D5W only : 50mg/250cc, light sensitive
-onset : 30~60secs
-duration : 1~10min
-titrate : 3~10mcg/kg/min
¨é Adverse reactions
-hypotension
-Thiocyanate and cyanide toxicity with high dose or long term use
: N/V, abd pain, dizziness, palpitation, metabolic acidosis
¨ê Nursing concerns
-light sensitive
-use prepared solution within 4hrs, discard(¹ö¸®´Ù) at 24hrs
3) Dobutamine(Dobutrex) 250mg/5ml
¨ç mechanism of action
-inotropic(±Ù¼öÃà)
-synthetic(ÇÕ¼º) cathecholamine
-beta-1(primary effect) : ¡èCO, SV, contractility, automacity
-beta-2(Nild dffect) : ¡éPCWP, CVP, SVR
-no marked increase in HR or BP
¨è Dosage
-mix in D5W or NSS
-onset : 1~10min
-duration : <10min
-titrate : 2.5~20mcg/kg/min
¨é Adverse reactions
-Hypersensitivity
-AF/Atrial Flutter
¨ê Nursing concerns
-correct hypovolemia
-titration based on hemodynamic response
-consider dose reduction if HR increases by 10%
-May increase insulin requirement
4) Dopamin (200mg/5ml)
¨ç mechanism of action
-direct action on alpha, beta and dopaminergic receptors
-effects is dose dependent
-endogeneous(³»Àμº) precursor(¼±±¸¹°Áú) of NE
-positive inotropic effect on myocardium(½É±Ù)
: increase CO with increase BP
-renal, mesenteric(Àå°£¸·), CO increase at low dose
¨è Dosage
-Low : 2~5 mcg/kg/min : dopaminergic, renal, mesenteric vasodilation, renal dose
-medium : 5~10mcg/kg/min, beta1, alpha Contractility dose
-High >10mcg/kg/min alpha, Vasoconstriction dose
 
Âü°íÀÚ·á Âü°íÀÚ·á ¾øÀ½
Çб³Á¤º¸ 2ÁÖ°£ ´Ù¿î¹ÞÀº ÇлýÀÇ Çб³Á¤º¸¸¦ º¸¿©ÁÝ´Ï´Ù.(5P ¼Ò¿ä)
ÀúÀÛ±Ç Á¤º¸ À§ Á¤º¸ ¹× °Ô½Ã¹° ³»¿ëÀÇ Áø½Ç¼º¿¡ ´ëÇÏ¿© ÇØÇÇÄ·ÆÛ½º´Â º¸ÁõÇÏÁö ¾Æ´ÏÇϸç, ÇØ´ç Á¤º¸ ¹× °Ô½Ã¹° ÀúÀ۱ǰú ±âŸ ¹ýÀû Ã¥ÀÓÀº ÀÚ·á µî·ÏÀÚ¿¡°Ô ÀÖ½À´Ï´Ù.
À§ Á¤º¸ ¹× °Ô½Ã¹° ³»¿ëÀÇ ºÒ¹ýÀû ÀÌ¿ë, ¹«´Ü ÀüÀ硤¹èÆ÷´Â ±ÝÁöµÇ¾î ÀÖ½À´Ï´Ù.ÀúÀÛ±ÇÄ§ÇØ, ¸í¿¹ÈÑ¼Õ µî ºÐÀï¿ä¼Ò ¹ß°ß½Ã °í°´¼¾ÅÍÀÇ ÀúÀÛ±ÇÄ§ÇØ ½Å°í¼¾Å͸¦ ÀÌ¿ëÇØ Áֽñ⠹ٶø´Ï´Ù.

±¸¸ÅÆò°¡(
0
)
±¸¸Å¹®ÀÇ(
0
)
Æ®·¢¹é(
0
)